The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, May 20, 2025, 12:00 Hrs [IST] GSK plc announced ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM).

GSK (GSK) plc announced the authorization of Blenrep by the Medicines and Healthcare products Regulatory Agency. “In the UK, Blenrep is approved for the treatment of adults with multiple myeloma ...

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma.

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM). This authorisation is said to be a global first for Blenrep ...